Video Reports

This article was reviewed by Uday Devgan, MD

Grant McArthur, PhD, Melanoma Unit, Peter MacCallum Cancer Centre, discusses significant results from the final analysis of the coBRIM trial, which evaluated the 5-year survival data of cobimetinib (Cotellic) plus vemurafenib (Zelboraf) in patients with BRAF V600-mutated advanced melanoma.

Gaudenz Danuser, PhD, chair of Bioinformatics at UT Southwestern Medical Center, discusses how the activation of RacP29S impacts the treatment of patients with melanoma.

Isabella C. Glitza, MD, assistant professor at MD Anderson Cancer Center, discusses a single-center phase I/Ib trial of concurrent intravenous and intrathecal nivolumab (Opdivo) for patients with metastatic melanoma and leptomeningeal disease.